Compare top CAR T-cell therapy doctors and prices in Israel. Find your best match here.
We'll hand-pick the best doctors based on your needs and budget.
Meet the experts behind this page
Medically reviewed by Fahad Mawlood
Medical Editor & Data ScientistTop doctors
14
Israel
Reviews
14,000+
From real patients
Compare prices for CAR T-cell therapy across top countries
Tap a country to view top doctors and prices
Get free personalized treatment plans and choose the best option. No commitment · No payments for our services
Show first:
Dr. Ram Ron specializes in CAR T-cell therapy at Sourasky Medical Center (Ichilov), bringing extensive expertise to this advanced treatment.
Dr. Ron Ram has performed several hundred stem cell transplants and published over 30 scientific articles in hematology and oncology.
Head of Pediatric Oncohematology at Dana Dwek Children's Hospital – Dr. Ronit El Hasid specializes in bone marrow and blood transplants for children.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Michael Shapira specializes in Bone Marrow Transplantation at Sourasky Medical Center (Ichilov), with extensive experience in the field.
Director of pediatric hematology oncology at Sourasky Medical Center – specializes in CAR T-cell therapy for children with blood disorders and sarcomas.
With 34 years of experience of experience, Dr. Aviv specializes in CAR T-cell therapy at Sourasky Medical Center (Ichilov Clinic).
Dr. Yair has made significant contributions to hematology, particularly in chronic lymphocytic leukemia, with numerous awards and published research.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.
He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.
He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Dr. Danylesko specializes in CAR T-cell therapy at Sheba Medical Center, focusing on personalized treatment approaches.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
Choosing a clinic abroad can be stressful. At Bookimed, with over 800K patients helped, we understand your concerns. We know how to find trusted doctors, the best price-quality options, and solutions for even complex cases. We’re here to guide you every step of the way.
Yan Matsiivskiy
Head of Medical Coordinator Team
4300++ patient journeys guided
3 years at Bookimed
142 patients from Israel have found their doctor through us this month
2 min Quiz
Tell us your goal, budget, timeline
Human Matching + AI
Our algorithm finds matches, coordinator verifies fit
Your Options Ready
Compare prices, packages, dates. Chat with your coordinator
Overwhelmed by choices?
Guiding your treatment
Medically trained personal coordinators
| Rank | Doctor | experience | Good Fit For | What Sets Them Apart | Clinic & Location | Consultation |
|---|---|---|---|---|---|---|
| #1 | 24 years of experience | CAR T-cell therapy | Specializes in advanced cellular therapies at a top oncology center, focusing on personalized treatment plans. | Israel | Price on request
| |
| #2 | 24 years of experience | Hematologic malignancies | Extensive experience in stem cell transplants with academic contributions including 30+ published articles. Fellowship-trained at New York Medical College. | Israel | Price on request
| |
| #3 | 38 years of experience | Pediatric CAR T-cell therapy | Leads the pediatric transplantation department with 300+ transplants performed. Published 50+ papers and member of key hematology associations. | Israel | Price on request
| |
| #4 | 36 years of experience | Bone Marrow Transplantation | Specializes in Bone Marrow Transplantation with senior-level expertise. Trained at prestigious Hadassah Medical Center and Hebrew University. | Israel | Price on request
| |
| #5 | 41 years of experience | Pediatric blood disorders & sarcomas | Leads Sourasky's pediatric hematology oncology department – trained at top global institutes for childhood cancers. Coordinates Israel's sarcoma treatment programs. | Israel | Price on request
| |
| #6 | 34 years of experience | CAR T-cell therapy | Specializes in oncohematology with decades of experience in advanced cellular therapies. Works at Israel's premier Sourasky Medical Center. | Israel | Price on request
| |
| #7 | 24 years of experience | Chronic lymphocytic leukemia | Specializes in chronic lymphocytic leukemia with multiple awards and research grants. Member of leading hematology associations. | Israel | Price on request
| |
| #8 | 23 years of experience | CAR T-cell therapy patients | Focuses on personalized CAR T-cell therapy approaches at Sheba Medical Center – one of Israel's leading hospitals for innovative cancer treatments. | Israel | Price on request
|
You do not need a specific CAR T-cell referral to begin. Any hematologist or community oncologist can initiate the process to a specialized center. However, a multidisciplinary team at an accredited Israeli hospital must confirm your final eligibility for treatment.
Bookimed Expert Insight: While any hematologist can refer you, selecting a doctor with a high volume of related procedures speeds up valid documentation. For example, Dr. Ivetta Danylesko at Sheba Medical Center has performed over 3,000 procedures. Working with such experienced specialists helps ensure your medical history meets specific clinical trials or protocol requirements faster.
Patient Consensus: Patients note that pushing a local oncologist to refer directly to a CAR T-cell team can help bypass general queues. Many emphasize that having all previous treatment lines documented is vital for the multi-center board review. It is also common for patients to plan for a three to four month wait even after the initial referral.
Verify Israeli CAR T-cell therapy doctors by confirming their board certification in hematology and oncology through the Scientific Council of the Israel Medical Association. Leading specialists often hold international memberships in the American Society of Hematology and have completed fellowship training at top US institutions.
Bookimed Expert Insight: Data shows that premier Israeli specialists often hold significant leadership roles in global organizations. For instance, Dr. Arnon Nagler at Sheba Medical Center served as the Chair for the European Society for Blood and Marrow Transplantation (EBMT) committees. This level of international leadership indicates that these doctors don't just follow protocols but actually help create the global standards for CAR T-cell therapy and transplant medicine.
Patient Consensus: Patients mention that top-tier doctors are very open about sharing their personal results and response rates. They noticed that experienced specialists often have many co-author credits on major clinical trials. Families emphasize that the most skilled pediatric doctors have deep experience in handling complex cases at dedicated children's hospitals.
When choosing a CAR T-cell therapy doctor in Israel, you should look for board-certified hematologists and oncologists with specialized training in cellular immunotherapy. Leading experts often lead bone marrow transplant departments and have extensive experience in treating complex blood cancers like leukemia and lymphoma.
Bookimed Expert Insight: Data shows that premier Israeli specialists combine clinical leadership with heavy research involvement. For example, Prof. Arnon Nagler at Sheba Medical Center pioneered reduced-intensity transplant protocols. Choosing a doctor who also serves as a department director ensures they oversee the entire cell processing and recovery cycle at JCI-accredited facilities.
Patient Consensus: Patients often emphasize the importance of finding a doctor familiar with bridging therapies used before the actual cell infusion. They note that feeling supported by a team experienced in managing post-infusion side effects made their recovery much smoother. Many were relieved to work with specialists who have personal experience running clinical trials for the latest cellular products.
Major public medical centers in Israel like Sheba and Sourasky (Ichilov) staff board-certified hematologists with international fellowships in cellular immunotherapy. These facilities operate specialized units for CAR T-cell therapy. Experts here maintain credentials from the American Society of Hematology and other global bodies.
Bookimed Expert Insight: Data shows that Israeli public centers often feature surgeons who also lead specialized research departments. For example, Dr. Herishanu Yair at Sourasky heads the CLL Department while managing CAR T-cell protocols. This dual role means patients receive care from doctors who directly contribute to the latest clinical protocols and published research.
Patient Consensus: Patients note that doctors at these centers speak English at a level comparable to US specialists. They often mention the long 6-8 month waitlists for public slots but feel the advanced cellular facilities are worth the wait. Many are surprised by how quickly centers like Sheba can manufacture the cells on-site.
Private CAR T-cell therapy consultations with senior Israeli specialists typically range from $500 to $1,350. The public sector offers significantly lower costs for residents through health funds. However, private sessions provide immediate access to department heads and personalized treatment plans without the long wait times.
Bookimed Expert Insight: Data shows that senior specialists in Tel Aviv often maintain dual roles as department heads and private consultants. Dr. Fredi Aviv and Dr. Herishanu Yair bring over 25 years of experience to these sessions. Choosing a private consult at a center like Sourasky allows patients to bypass the standard 6-month public approval queue.
Patient Consensus: Patients note that while public sector co-pays are minimal, the bureaucracy can delay urgent care. Many choose private sessions to get a treatment plan started in days. They describe the experience as worth the cost for the direct time spent with a professor.
Patients should expect a high level of English proficiency from CAR T-cell therapy specialists in Israel. Most leading doctors hold American Board certifications or have completed fellowships at prestigious institutions like Stanford University and SUNY Brooklyn. Hospitals provide dedicated interpretation services for international patients to navigate complex treatment stages.
Bookimed Expert Insight: Data shows that senior hematologists in Israel often have dual training from both Israeli and North American institutions. For example, Dr. Arnon Nagler at Sheba Medical Center is a Stanford-trained pioneer, while Dr. Ronit El Hasid at Sourasky practiced at City of Hope in Los Angeles. This specific international background means they are comfortable using English as a primary language for medical discussions.
Patient Consensus: Patients find that while lead doctors speak excellent English, some nursing staff may have more limited language skills. Many suggest using a translation app for quick bedside needs but note that hospital coordinators are essential for understanding complex physician instructions.
Israel leads CAR T-cell innovation by running early-phase trials with homegrown constructs for blood cancers and solid tumors. Top experts like Dr. Ron Ram at Sourasky Medical Center (Ichilov) and specialists at Sheba Medical Center develop proprietary vectors. These programs often provide faster access than commercial therapies from the US.
Bookimed Expert Insight: A unique pattern in Israel is the integration of high-level international training within local research clinics. For example, Dr. Ron Ram and Dr. Arnon Nagler both completed fellowships at Stanford University, while Dr. Ronit El Hasid trained at City of Hope. This global expertise allows Israeli centers to successfully run dual US-Israel clinical trials for complex off-the-shelf and bispecific CAR-T products.
Patient Consensus: Patients note that Israeli doctors often provide access to logic-gated constructs after US programs decline their cases. Relatives say the medical teams quickly manage side effects like cytokine release syndrome during phase 1 trials. Many emphasize having a translator ready because consent forms for early-stage studies are frequently in Hebrew.